Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KontRASt-03: JDQ443 Combinations in KRAS G12C Mutant Solid Tumors
NCT05358249Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2022
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of opnurasib in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), sponsored by Novartis. Started Oct 2022; status: terminated.
02
Drugs
opnurasib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05358249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358249.